Loading
Pi3k/akt/mtor Signaling in Cancer / Chronic Lymphocytic Leukemia Research · Journal article
Nature Chemical Biology · August 13, 2026
Raises a question worth testing. It does not answer one.
This study describes a photoproximity labeling strategy to identify cancer-specific protein interactors of c-Myc and reports that the kinase SLK promotes c-Myc stabilization through a splicing-dependent mechanism. The findings are mechanistic and exploratory, establishing a candidate therapeutic axis in cell culture models without clinical validation or efficacy data.
Mechanistic cell-based study with patient data correlation. Healthy prostate cell lines and cancerous prostate cell lines; human cancer patient genomic data analyzed post hoc. Intervention: Photoproximity labeling to capture c-Myc interactome; functional manipulation of SLK in cell lines. Compared with: Healthy versus cancerous prostate cell line interactomes.
SLK identified as cancer-specific c-Myc interactor using context-dependent μMap photoproximity labeling in prostate cell lines SLK selectively promotes c-Myc stabilization at protein level and drives epithelial morphology in cancer cells SLK stabilization of c-Myc is driven by change in SLK splicing rather than expression at protein or RNA levels
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This identifies SLK as a candidate therapeutic target for cancer; however, no efficacy data in patient samples or animal models is presented, and the mechanism is still at the level of cell-based mechanistic discovery.
This is a mechanistic discovery study using novel proteomics methodology to identify a protein interaction and propose a regulatory mechanism; it lacks clinical outcome data, patient treatment results, or even cell-based validation of therapeutic efficacy.
As stated by the source record.
This identifies SLK as a candidate therapeutic target for cancer; however, no efficacy data in patient samples or animal models is presented, and the mechanism is still at the level of cell-based mechanistic discovery.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Transcription factors (TFs) have long been aspirational therapeutic targets for the treatment of diseases, as their dysregulation is a common mechanism for altered cell states. Despite this, many TFs implicated in disease have disordered structures and lack canonical binding pockets, rendering them non-trivial targets for small molecule-based therapies. Directly inhibiting TF function has proven difficult, but indirect inhibition by targeting the effector molecules that modulate TF function is a promising, yet underexplored, alternative approach. Here we report a strategy for capturing cancer-specific protein-protein interactions using context-dependent μMap photoproximity labeling. Using an intein-based method for catalyst conjugation in biochemically intact nuclei, we demonstrate that we can capture unique protein interactomes of c-Myc in healthy and cancerous prostate cell lines, and that these unique interactors can be mined to identify druggable vulnerabilities. We find that a cancer specific Myc interactor, SLK, selectively promotes c-Myc stabilization at the protein level, drives epithelial morphology, and is essential for tumorigenesis, validating it as a viable therapeutic target. Importantly, this stabilization is driven by a change in SLK splicing rather than expression at the protein or RNA levels. Furthermore, analysis of cancer patient data shows a strong correlation between this splice isoform and expression of c-Myc targets, suggesting this novel regulatory axis is operative across human cancer.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.